Semi-Annual Statement Of Cash Flows

Delta-Fly Pharma, Inc. - Filing #7597815

Concept As at
2022-03-31
2021-04-01 to
2022-03-31
2020-04-01 to
2021-03-31
As at
2021-03-31
As at
2020-03-31
Semi-annual statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-964,064,000 JPY
-859,372,000 JPY
Depreciation
1,672,000 JPY
2,005,000 JPY
Interest expenses
JPY
43,000 JPY
Foreign exchange losses (gains)
-422,000 JPY
3,455,000 JPY
Decrease (increase) in trade receivables
JPY
110,000,000 JPY
Other, net
13,818,000 JPY
36,156,000 JPY
Subtotal
-943,127,000 JPY
-718,052,000 JPY
Interest paid
JPY
-43,000 JPY
Net cash provided by (used in) operating activities
-940,399,000 JPY
-726,649,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
JPY
-505,000 JPY
Net cash provided by (used in) investing activities
JPY
-505,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
JPY
-5,700,000 JPY
Purchase of treasury shares
-173,000 JPY
JPY
Net cash provided by (used in) financing activities
119,857,000 JPY
875,313,000 JPY
Effect of exchange rate change on cash and cash equivalents
422,000 JPY
-3,455,000 JPY
Net increase (decrease) in cash and cash equivalents
-820,119,000 JPY
144,703,000 JPY
Cash and cash equivalents
1,268,492,000 JPY
2,088,612,000 JPY
1,943,908,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.